Pharmacogenomic Biomarkers in Docetaxel Treatment of Prostate Cancer: From Discovery to Implementation

Genes - Switzerland
doi 10.3390/genes10080599
Full Text
Abstract

Available in full text

Categories
Genetics
Date
Authors
Publisher

MDPI AG

Related search

Prostate Cancer: From Diagnosis to Treatment

Onkourologiya
OncologyRadiologyUrologyNuclear MedicineNephrologyImagingSurgery
2019English

Docetaxel and Doxorubicin Codelivery by Nanocarriers for Synergistic Treatment of Prostate Cancer

Frontiers in Pharmacology
Pharmacology
2019English

Case Report: Responses to Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer After Extensive Docetaxel Treatment

Clinical Genitourinary Cancer
OncologyUrology
2011English

Biomarkers of Aggressiveness in Prostate Cancer

2011English

Salvage Therapy for Castration-Refractory Prostate Cancer Resistant to Docetaxel

Japanese Journal of Urology
Urology
2013English

Pcn336 - Treatment of Metastatic Castration-Resistant Prostate Cancer Patients Previously Treated With Docetaxel in Portugal

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Castration-Dependent Pharmacokinetics of Docetaxel in Patients With Prostate Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2010English

Management of Docetaxel Failures in Metastatic Castrate-Resistant Prostate Cancer

Urologic Clinics of North America
Urology
2012English

Prostate Cancer Biomarkers– A Bench to Bedside Perspective

Cancer Science & Research: Open Access
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy